Yaxiao Lu
State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine/Department Of Lymphoma, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.
Journal: Frontiers in immunology
Published: January 18, 2026
Early Detection and Central Nervous System Prophylaxis in Patients With High-Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis.
Journal: Hematological oncology
Published: October 11, 2024
OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma.
Journal: Clinical immunology (Orlando, Fla.)
Published: May 10, 2022
PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.
Journal: Clinical and translational medicine
Published: December 21, 2021
A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma.
Journal: Frontiers in immunology
Published: November 11, 2021
Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma.
Journal: American journal of hematology
Published: June 26, 2021
An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy.
Journal: Frontiers in oncology
Published: May 12, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026